智通财经APP获悉，再鼎医药(09688)涨超5%，截至发稿，涨4.75%，报20.95港元，成交额631.93万港元。
消息面上，1月23日，再鼎医药宣布，美国食品药品监督管理局(FDA)已授予ZL-1310孤儿药资格认定(ODD)，ZL-1310是一款高活性的具有同类首创潜力的DLL3 ADC，用于治疗小细胞肺癌(SCLC)。ZL-1310将有资格获得某些开发激励措施，包括免除处方药用户付费法案(PDUFA)的注册申请费，获得相应临床研究的税收抵免，以及在产品获批后有望被授予在美国市场的七年独占期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.